ArticlePediatric research2026
Blood fatty acid changes in preterm infants in a trial of enteral DHA supplementation.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVery preterm infants miss the peak in-utero supply of omega-3 docosahexaenoic acid (DHA) and omega-6 arachidonic acid (AA), and are thought to receive low amounts after birth.
methodsIn a randomized controlled trial of 1077 babies born <29 weeks' gestation we assessed the DHA and AA concentrations in whole blood before and after (36 weeks' post menstrual age, PMA) enteral emulsion intervention with 60 mg/kg/d of DHA compared with no DHA soy oil.
resultsPrior to the intervention, all infants had similar mean DHA (2.8% of total fatty acids) and mean AA (intervention 10.45%; control 10.42%) concentrations. By 36 weeks', mean DHA of intervention group infants increased to 3.86%, while it decreased to 2.53% in the control group (mean difference 1.33%, 95% CI 1.27 to 1.40, p < 0.0001). AA was lower at 36 weeks' than at enrolment, with the decrease marginally more pronounced in the intervention group (8.11%) compared with the control group (8.84%, mean difference -0.71%, 95% CI -0.86 to -0.57, p < 0.0001).
conclusionAll fatty acids regressed towards a new diet-dependent mean at 36 weeks regardless of the initial level. DHA supplementation successfully prevented the typical decline in DHA and modestly exacerbated the decline in AA.
trial registrationThe N3RO Trial is registered at the Australian New Zealand Clinical Trial Registry as ACTRN12612000503820 (anzctr.org.au), 9 May 2012. IMPACT: High-dose DHA supplementation in preterm infants prevents the typical postnatal decline in DHA. This study provides evidence from over 1000 infants across Australia, New Zealand, and Singapore. The findings have direct implications for optimizing neonatal nutrition in very preterm populations.
Identifiers
42249024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.